TOKYO, July 16, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the drug discovery research for Lecanemab (product name: “LEQEMBI®”), a humanized anti-human soluble amyloid B (AB)protofibril monoclonal antibody indicated for early Alzheimer’s disease (early AD*), which was co-developed by Eisai and BioArctic AB (Headquarters: Sweden…
Read More
